key: cord-0872873-i8ggae40 authors: Zhang, Zehui; Wang, Xiaoqin; Wei, Xiaojun; Zheng, Sophia W.; Lenhart, Brian J.; Xu, Peisheng; Li, Jie; Pan, Jing; Albrecht, Helmut; Liu, Chang title: Multiplex Quantitative Detection of SARS-CoV-2 Specific IgG and IgM Antibodies based on DNA-assisted Nanopore Sensing date: 2021-03-03 journal: Biosens Bioelectron DOI: 10.1016/j.bios.2021.113134 sha: 5fac1be37b4aad9cbe21223dd5e501f2b41ccb31 doc_id: 872873 cord_uid: i8ggae40 The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread into a global pandemic. Early and accurate diagnosis and quarantine remain the most effective mitigation strategy. Although reverse transcriptase polymerase chain reaction (RT-qPCR) is the gold standard for COVID-19 diagnosis, recent studies suggest that nucleic acids were undetectable in a significant number of cases with clinical features of COVID-19. Serologic assays that detect human antibodies to SARS-CoV-2 serve as a complementary method to diagnose these cases, as well as to identify asymptomatic cases and qualified convalescent serum donors. However, commercially available enzyme-linked immunosorbent assays (ELISA) are laborious and non-quantitative, while point-of-care assays suffer from low detection accuracy. To provide a serologic assay with high performance and portability for potential point-of-care applications, we developed DNA-assisted nanopore sensing for quantification of SARS-CoV-2 related antibodies in human serum. Different DNA structures were used as detection reporters for multiplex quantification of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the nucleocapsid protein of SARS-CoV-2 in serum specimens from patients with conformed or suspected infection. Comparing to a clinically used point-of-care assay and an ELISA assay, our technology can reliably quantify SARS-CoV-2 antibodies with higher accuracy, large dynamic range, and potential for assay automation. Abstract: 22 The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome 23 coronavirus 2 (SARS-CoV-2) has spread into a global pandemic. Early and accurate 24 diagnosis and quarantine remain the most effective mitigation strategy. Although Alkynyl modified DNA (100 µM, 3.3 µL) was first added into HEPES buffer (2 µL). 10 µg/mL, 1 µg/mL, 100 ng/mL,10 ng/mL) and IgM antibody of different 185 concentrations (10 µg/mL, 5 µg/mL, 1 µg/mL, 100 ng/mL, 50 ng/mL). The formation of nanopore sensor, data recording and analysis were previously In this study, we selected SARS-CoV-2 N protein specific IgG and IgM antibodies as 235 biomarkers to demonstrate a multiplex quantitative nanopore assay, aiming to 236 achieve high sensitivity and high specificity comparable to lab-based technologies. nanopore biosensor to indicate IgG and IgM concentrations, respectively (Fig. 1) . 243 The highly specific multiplex quantification of SARS-CoV-2 antibodies is based on the the guest molecule. This process is characterized by the level 1 of signal A (Fig. 2a) . 258 Next, after separation, the modified ssDNA exit the nanopore to the trans side, while 259 cucurbituril[6] oscillates inside the lumen for a period of time before exiting back to the 260 cis side of the nanopore (Fig. S2a) . This process corresponds to the level 2 of signal 261 A (Fig. 2a) . Upon analyzing ~100 events of signal A in histograms, the average 262 current blockade of level 1 (I 1 /I 0 ) and level 2 (I 2 /I 0 ) were found to be (98.1±0.6)% and 263 J o u r n a l P r e -p r o o f (71.6±0.1)% with Gaussian distribution, respectively (Fig. 2b) . The average dwell 264 time for level 1 (T 1 ) and level 2 (T 2 ) were (300.89±30.1) ms and (20.17±1.3) ms, 265 respectively, corresponding to exponential fitting (Fig. 2c) . 266 The difference between signal A and signal B is caused by the different modification (Fig. 2f) . We anticipate that such difference in signal patterns was caused by To quantitatively measure SARS-CoV-2 IgG and IgM in patient samples, standard (Fig. 3a&b, Fig. S3&S4 ). Based on calculation from limit of blanks,(Armbruster and (Fig. 3d, Fig. S5&S6 and Table S1 ). In three COVID-19 positive patients confirmed However, using the DNA-assisted nanopore assay, we were able to detect IgG and/or 301 IgM in sixteen of them. It is worthy to notice that among all possible patients, the five 302 patients that are detectable by IgG ELISA also exhibited highest IgG levels according not commonly seen in clinical serum samples (Fig. S7) . beads-based immunoprecipitation can ensure easy adoption of assay automation. Upon incorporation with microfluidics and scaled-up production, the cost of this 335 nanopore assay is expected to be slightly lower than that of ELISA (~$8 per test). Notably, this assay can also be readily modified with minimal optimization to quantify 337 SARS-CoV-2 antigens in nasopharyngeal swab samples. In the performance evaluation study using patients' samples, the DNA-assisted 339 nanopore assay was applied to detect IgG and IgM antibodies against the N protein. For comparison, a LFA and an ELISA made using the same biorecognition element 341 that targets the same antibodies were also used to test the same human samples. 434 Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in 435 China: A Report of 1014 Cases The Impact of 437 COVID-19 on Radiology Trainees A 443 serological assay to detect SARS-CoV-2 seroconversion in humans Limit of blank, limit of detection and limit of quantitation 448 Placement of oppositely charged aminoacids at a polypeptide termini determines the 449 voltage-controlled braking of polymer transport through nanometer-scale pores Presumed 452 Asymptomatic Carrier Transmission of COVID-19 Detection of Nucleocapsid Antibody to 455 SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. 456 medRxiv Sensitivity in Detection of Antibodies to 459 Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in 460 Patients With Coronavirus Disease Flu virus finally sequenced in its native form Technique could help to 463 unpick role of enigmatic chemical modifications in genetic material The convalescent sera option for containing COVID-19 Detection of 2019 471 novel coronavirus (2019-nCoV) by real-time RT-PCR Three decades of nanopore sequencing The Nucleocapsid Protein of SARS-CoV-2: a 475 Target for Vaccine Development Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer 478 interferometry Quantitative analysis of four protein biomarkers: 480 An automated microfluidic cartridge-based method and its comparison to colorimetric ELISA An ace in the hole for DNA sequencing Multiplex bead array assays: Performance evaluation and 484 comparison of sensitivity to ELISA Sensitivity of Chest CT for 486 COVID-19: Comparison to RT-PCR Highly parallel direct RNA sequencing 491 on an array of nanopores The species Severe acute respiratory 496 syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Analyte-Triggered DNA-Probe 499 Release from a Triplex Molecular Beacon for Nanopore Sensing Simultaneous Sensing of Multiple 502 Cancer Biomarkers by a Single DNA Nanoprobe in a Nanopore Profiling Early Humoral Response to Diagnose 507 Novel Coronavirus Disease (COVID-19) Nanopore analytics: sensing of single molecules Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis 514 Nanoscopic Porous Sensors Nanopore Fabrication and 516 Application as Biosensors in Neurodegenerative Diseases Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1: a systematic review Persistence and decay of human antibody 522 responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients A Universal Strategy for Aptamer Nanopore Sensing through Host-Guest Interactions inside α-Hemolysin 529 Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery 530 from COVID-19 Direct sensing of cancer biomarkers 532 in clinical samples with a designed nanopore Simultaneous 535 Quantification of Multiple Cancer Biomarkers in Blood Samples through DNA Angewandte Chemie Quantification of antibody avidities and accurate 540 detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates a3 Oxford Nanopore MinION Sequencing and 543 Serum IgA, IgM, and IgG responses in COVID-19 High clinical performance and quantitative 549 assessment of antibody kinetics using a dual recognition assay for the detection of 550 SARS-CoV-2 IgM and IgG antibodies Sequence-Specific Recognition of HIV-1 DNA 552 with Solid-State CRISPR-Cas12a-Assisted Nanopores (SCAN) SARS-CoV-2 specific antibody responses in COVID-19 558 patients. medRxiv Diagnostics for SARS-CoV-2 detection: A 560 comprehensive review of the FDA-EUA COVID-19 testing landscape SARS-CoV-2-specific ELISA development Designs, formats and applications of lateral flow 568 assay: A literature review Metagenomic insights to understand transient influence of Yamuna River 571 on taxonomic and functional aspects of bacterial and archaeal communities of River Ganges Real-world evaluation of a novel technology for 577 quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a 578 cohort of patients presenting with COVID-19 syndrome Treatment of 5 Critically Ill 582 Patients With COVID-19 With Convalescent Plasma Clinical usefulness of fully automated 585 chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 586 patients Recent trends in nanopores for biotechnology Rapid and quantitative detection of SARS-CoV-2 specific IgG for 591 convalescent serum evaluation Nanopore-based Strategy for 593 Diagnosing COVID-19: The Disease 597 and Tools for Detection Phi29 DNA-Packaging Motor for Real-Time Detection of Single Colon Cancer Specific 600 Antibody in Serum Nanopores: A journey towards DNA sequencing Liu, 604 C., 2020a. Enabling Nanopore for Sensing Individual Amino Acids by a Derivatization 605 Strategy N-Terminal Derivatization-Assisted Identification of 608 Individual Amino Acids Using a Biological Nanopore Sensor Insight into 610 the effects of electrochemical factors on host-guest interaction induced signature events in a 611 biological nanopore Graphene Nanopores for Protein Antibody Detection and Dynamic Characteristics in Patients With 616 Coronavirus Disease False negative of RT-PCR and prolonged nucleic acid 618 conversion in COVID-19: Rather than recurrence Measuring Binding 621 Constants of Cucurbituril-Based Host-Guest Interactions at the Single-Molecule Level with 622 Nanopores Intelligent identification of 624 multi-level nanopore signatures for accurate detection of cancer biomarkers Enhanced Sensitivity in Nanopore 627 Sensing of Cancer Biomarkers in Human Blood via Click Chemistry Antibody Responses to SARS-CoV-2 in Patients With 631 Novel Coronavirus Disease A pneumonia outbreak associated with a new 636 coronavirus of probable bat origin